Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
7540554
Reference Type
Journal Article
Title
Cancer multitarget pharmacology in prostate tumors: tyrosine kinase inhibitors and beyond
Author(s)
Bologna, M; Vicentini, C; Muzi, P; Pace, G; Angelucci, A; ,
Year
2011
Is Peer Reviewed?
Yes
Journal
Current Medicinal Chemistry
ISSN:
0929-8673
EISSN:
1875-533X
Publisher
BENTHAM SCIENCE PUBL LTD
Location
SHARJAH
Volume
18
Issue
19
Page Numbers
2827-2835
Language
English
PMID
21651496
DOI
10.2174/092986711796150487
Web of Science Id
WOS:000292765200002
URL
http://www.eurekaselect.com/openurl/content.php?genre=article&issn=0929-8673&volume=18&issue=19&spage=2827
Exit
Abstract
Tyrosine kinase inhibitors are currently one of the most important classes of cancer drugs, essentially because many kinases and regulators are molecules related to frequently mutated oncogenes and tumor suppressors. Many experiments and clinical data in different tumors show that better cancer therapy can be obtained by blocking several tumor cell biochemical pathways at once, accurately selecting critical targets and adjusting drug dosages for the best results. Through our direct experience in experimental models of prostate cancer (PCa), we discuss in this review the issues of tyrosine kinase inhibition in neoplastic cells and illustrate the opportunities to extend cancer proliferation control to other key biological targets of clinical interest, aiming at the realization of better polypharmacology applications in cancer chemotherapy. Briefly, in this review the main experimental evidences on the efficacy of tyrosine kinase inhibitors (TKIs) on PCa are described, together with a reasoned analysis of biological data which may be useful for a general extension to other clinical areas of cancer multitargeted and possibly individualized polychemotherapy.
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity